PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

IMG-20170806-WA0009
20170729 203524
20170730 182955
DJI 0006
20180131 164914
DJI 0083
  • Human medicines European public assessment report (EPAR): Grasustek, pegfilgrastim, Neutropenia, Date of authorisation: 20/06/2019, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
  • Summary of opinion: Pedmarqsi,sodium thiosulfate, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Omvoh,mirikizumab, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Procter & Gamble Manufactura S. de R.L. de C.V. - 650837 - 03/27/2023
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Procter & Gamble Manufactura S. de R.L. de C.V. - 650837 - 03/14/2023
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Summary of opinion: Sugammadex Adroiq,sugammadex, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Tenkasi (previously Orbactiv),oritavancin, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Ultomiris,ravulizumab, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Ultomiris,ravulizumab, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Breyanzi,lisocabtagene maraleucel, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Epysqli, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Entresto,sacubitril,valsartan, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Summary of opinion: Neparvis,sacubitril,valsartan, 30/03/2023, Positive
    Source: EMA - New medicines: human Published on 2023-03-31
  • Timeline of Selected FDA Activities and Significant Events Addressing Substance Use and Overdose Prevention
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • FDA Voices
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-30 By FDA
Older posts
Theme: Scaffold by Danny Cooper.